Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
February 12, 2025 1:46 PM ESTStifel analyst Rick Wise reiterated a Buy rating and $90.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Edwards' 4Q24 performance checked all the critical boxes, including: (1) mid-single-digit TAVR growth (5.3%), despite a 12.1% 4Q23 comp and selling day headwind, suggests that TAVR growth... More
